published meta-analysis   sensitivity analysis   studies

Lopinavir/ritonavir plus hydroxychloroquine in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsREMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93] 0.58[0.36; 0.93]REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 202010%406NAnot evaluable deaths (time to event analysis only)detailed resultsREMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93] 0.58[0.36; 0.93]REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 202010%406NAnot evaluable clinical improvementdetailed resultsREMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06] 0.63[0.37; 1.06]REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 202010%406NAnot evaluable clinical improvement (14-day)detailed resultsREMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06] 0.63[0.37; 1.06]REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 202010%406NAnot evaluable hospital dischargedetailed resultsREMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.43; 0.92] 0.63[0.43; 0.92]REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 202010%406NAnot evaluable serious adverse eventsdetailed resultsREMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.97 [0.22; 4.33] 0.97[0.22; 4.33]REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 202010%389NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:24 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 1145 - roots T: 290